Glass House Brands (GLAS) Other Non-Current Liabilities (2020 - 2026)

Glass House Brands' (GLAS) quarterly Other Non-Current Liabilities came in at $36.0 million in Q1 2026, up 42.67% year-on-year from $25.3 million in Q1 2025, and up 7.85% on a QoQ basis from $33.4 million in Q4 2025.

Glass House Brands (GLAS) Other Non-Current Liabilities (2020 - 2026) Analysis & Trends

Glass House Brands (GLAS) has 7 years of Other Non-Current Liabilities data on file, last reported at $36.0 million in Q1 2026.

  • On a quarterly basis, Other Non-Current Liabilities rose 42.67% year-over-year to $36.0 million in Q1 2026; TTM through Mar 2026 was $36.0 million, a 42.67% increase from a year earlier, with the FY2025 full-year figure at $33.4 million, up 60.11% from the prior year.
  • Other Non-Current Liabilities for Q1 2026 stood at $36.0 million, up from $33.4 million in the prior quarter.
  • Over the last five years, Other Non-Current Liabilities for GLAS reached as high as $44.9 million in Q1 2022 and fell as low as -$31122.4 billion in Q3 2022.
  • Historically, Other Non-Current Liabilities has averaged -$2067.4 billion across 5 years, with a median of $22.5 million in 2023.
  • On a YoY basis, Other Non-Current Liabilities climbed as much as 3808.88% in 2022 and fell as far as 79319112.67% in 2022.
  • Year by year, Other Non-Current Liabilities stood at $14.7 million in 2022, then surged by 136.0% to $34.6 million in 2023, then plunged by 39.67% to $20.9 million in 2024, then soared by 60.11% to $33.4 million in 2025, then advanced by 7.85% to $36.0 million in 2026.
  • Per Business Quant data, the three most recent Other Non-Current Liabilities figures were $36.0 million in Q1 2026, $33.4 million in Q4 2025, and $31.6 million in Q3 2025.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Haleon 89.28 Bn 87.42 Bn -
2 Teva Pharmaceutical Industries 35.97 Bn 32.23 Bn 1.97 Bn
3 Zoetis 32.42 Bn 30.48 Bn 1.62 Bn
4 Takeda Pharmaceutical 27.48 Bn 23.42 Bn 4.39 Bn
5 United Therapeutics 22.89 Bn 20.73 Bn 648.10 Mn
6 RedHill Biopharma 22.11 Bn 22.11 Bn -
7 Viatris 20.44 Bn 18.64 Bn 1.16 Bn
8 Neurocrine Biosciences 17.76 Bn 16.44 Bn 800.70 Mn
9 Elanco Animal Health 12.62 Bn 12.19 Bn 785.00 Mn
10 Glass House Brands 873.84 Mn 845.91 Mn 10.02 Mn

Historic Data

Download Data
DateValue
Mar 31, 2026 36.04 Mn
Dec 31, 2025 33.41 Mn
Sep 30, 2025 31.60 Mn
Jun 30, 2025 28.24 Mn
Mar 31, 2025 25.26 Mn
Dec 31, 2024 20.87 Mn
Sep 30, 2024 20.19 Mn
Jun 30, 2024 6.62 Mn
Mar 31, 2024 6.47 Mn
Dec 31, 2023 34.59 Mn
Sep 30, 2023 -4,023.66 Bn
Jun 30, 2023 22.51 Mn
Mar 31, 2023 4.88 Mn
Dec 31, 2022 14.66 Mn
Sep 30, 2022 -31,122.40 Bn
Jun 30, 2022 44.06 Mn
Mar 31, 2022 44.91 Mn
Dec 31, 2021 1.45 Mn
Sep 30, 2021 39.24 Mn
Mar 31, 2021 1.15 Mn